Evoltra



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 26.7%
Acute Myeloid Leukaemia 25.2%
Acute Lymphocytic Leukaemia 9.9%
Prophylaxis 9.2%
Acute Leukaemia 6.9%
Drug Use For Unknown Indication 3.7%
Bone Marrow Conditioning Regimen 3.2%
Antifungal Prophylaxis 2.1%
Infection 2.0%
Pyrexia 1.9%
Haematological Malignancy 1.4%
Prophylaxis Against Graft Versus Host Disease 1.2%
Pain 1.1%
Hypertension 0.9%
Acute Lymphocytic Leukaemia Recurrent 0.9%
Acute Myeloid Leukaemia Recurrent 0.8%
Antibiotic Therapy 0.8%
Nausea 0.7%
Antibiotic Prophylaxis 0.7%
Antiviral Prophylaxis 0.7%
Sepsis 12.5%
Thrombocytopenia 11.2%
Respiratory Failure 7.8%
Pyrexia 7.6%
Multi-organ Failure 6.8%
Septic Shock 6.5%
Pancytopenia 6.3%
Death 4.2%
Renal Failure 4.2%
Neutropenia 3.9%
Infection 3.7%
Acute Myeloid Leukaemia 3.4%
Pneumonia 3.1%
Cerebral Haemorrhage 2.9%
Febrile Neutropenia 2.9%
Tumour Lysis Syndrome 2.9%
Cardiac Failure 2.6%
Neutropenic Sepsis 2.6%
Vomiting 2.6%
Neutropenic Colitis 2.3%
Secondary
Acute Myeloid Leukaemia 27.2%
Product Used For Unknown Indication 24.1%
Bone Marrow Conditioning Regimen 9.9%
Acute Lymphocytic Leukaemia 8.1%
Prophylaxis 6.6%
Drug Use For Unknown Indication 3.4%
Haematological Malignancy 2.6%
Antifungal Prophylaxis 2.1%
Prophylaxis Against Graft Versus Host Disease 2.0%
Acute Leukaemia 1.8%
B-cell Lymphoma 1.8%
Immunosuppressant Drug Therapy 1.6%
Acute Myeloid Leukaemia Recurrent 1.3%
Myelodysplastic Syndrome 1.3%
Non-hodgkin's Lymphoma 1.2%
Antibiotic Prophylaxis 1.1%
Prophylaxis Of Nausea And Vomiting 1.1%
Hypertension 1.0%
T-cell Lymphoma 1.0%
Acute Lymphocytic Leukaemia Recurrent 0.9%
Septic Shock 12.8%
Thrombocytopenia 9.9%
Sepsis 8.5%
Acute Myeloid Leukaemia Recurrent 7.8%
Pancytopenia 7.1%
Pyrexia 7.1%
Respiratory Failure 6.4%
Neutropenia 5.0%
Adenovirus Infection 4.3%
Renal Failure 3.5%
Vomiting 3.5%
Axonal Neuropathy 2.8%
Epilepsy 2.8%
Fasciitis 2.8%
Multi-organ Failure 2.8%
Shock 2.8%
Sinus Tachycardia 2.8%
Transaminases Increased 2.8%
Acute Myeloid Leukaemia 2.1%
Bacteraemia 2.1%
Concomitant
Acute Myeloid Leukaemia 100.0%
Infection 100.0%
Interacting
Acute Myeloid Leukaemia 40.0%
Product Used For Unknown Indication 40.0%
Drug Use For Unknown Indication 20.0%
Thrombocytopenia 100.0%